All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Does enasidenib and azacitidine sequential therapy improve outcomes in older patients with IDH2 AML?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Eytan Stein, Memorial Sloan Kettering Cancer Center, New York, US. We asked, Does enasidenib and azacitidine sequential therapy improve outcomes in older patients with IDH2 AML?
Does enasidenib and azacitidine sequential therapy improve outcomes in older patients with IDH2 AML?
Stein discusses the results of a study evaluating the efficacy of enasidenib monotherapy with a response-adapted addition of azacitidine in older patients with newly diagnosed IDH2-mutated AML.
More about...
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox